Dr. Robert H. Vonderheide is the the co-leader of the Immunobiology Program, the vice chief for Research, the Hanna Wise Professor in Cancer Research, and the director of the Abramson Cancer Center at the University of Pennsylvania.
Dr. Vonderheide is an expert in immunobiology, and his work explores how CD40, GM-CSF, PD-1, CTLA-4, and CD25 regulate the tumor environment and immune activity. He has also helped translate his work into novel immunotherapies including vaccines, antibodies, and adoptive T cells which have been used to treat patients with melanoma, pancreatic cancer and other cancers. In addition to being a member of CRI’s Scientific Advisory Council, Dr. Vonderheide serves on the CLIP Grant Review Committee and is a member of CRI’s Clinical Leadership Committee.
Immunology is now part of the fabric of cancer biology. The clinical results we’ve seen with immunotherapy are absolutely unprecedented. We can now, hand on heart, honestly have discussions with patients about, ‘We might be able to cure you.’
¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.